Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV Interventional Post Approval Trial to Investigate Effectiveness and Safety of Vericiguat Therapy in Indian Patients With Chronic Heart Failure With Reduced Ejection Fraction After a Worsening Heart Failure Event.

NCT05658458 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT05658458
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05658458 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV Interventional Post Approval Trial to Investigate Effectiveness and Safety of Vericiguat Therapy in Indian Patients With Chronic Heart Failure With Reduced Ejection Fraction After a Worsening Heart Failure Event.
Lead sponsor
Bayer
Phase
Phase 4
Overall status
Completed
Start date
December 16, 2022
Completion date
September 19, 2024
Enrollment
205 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

chronic heart failure with reduced ejection fraction, worsening heart failure